Nature Communications (Jul 2020)
Tumors induce de novo steroid biosynthesis in T cells to evade immunity
- Bidesh Mahata,
- Jhuma Pramanik,
- Louise van der Weyden,
- Krzysztof Polanski,
- Gozde Kar,
- Angela Riedel,
- Xi Chen,
- Nuno A. Fonseca,
- Kousik Kundu,
- Lia S. Campos,
- Edward Ryder,
- Graham Duddy,
- Izabela Walczak,
- Klaus Okkenhaug,
- David J. Adams,
- Jacqueline D. Shields,
- Sarah A. Teichmann
Affiliations
- Bidesh Mahata
- Department of Pathology, University of Cambridge
- Jhuma Pramanik
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Louise van der Weyden
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Krzysztof Polanski
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Gozde Kar
- EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton
- Angela Riedel
- Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre
- Xi Chen
- Department of Biology, Southern University of Science and Technology
- Nuno A. Fonseca
- EMBL-European Bioinformatics Institute, Wellcome Genome Campus, Hinxton
- Kousik Kundu
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Lia S. Campos
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Edward Ryder
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Graham Duddy
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Izabela Walczak
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Klaus Okkenhaug
- Department of Pathology, University of Cambridge
- David J. Adams
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- Jacqueline D. Shields
- Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research Centre
- Sarah A. Teichmann
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton
- DOI
- https://doi.org/10.1038/s41467-020-17339-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Multiple mechanisms of immune evasion exploited by cancer cells have been described. Here, the authors show that genetic inactivation or pharmacological inhibition of tumor-induced Th2-mediated de novo steroidogenesis are sufficient to restore an efficient anti-tumor immune response and restrict tumor growth.
